Physician profile
Yanique Walker
NPI 1134846041
$11,830.89
in general payments reported to CMS, 2019-2025
27 companies · $3,953 in 2025
The $3,953 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $128 · 2023: $3,481 · 2024: $4,268 · 2025: $3,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,534.55 |
| Education | $167.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,179.15 | 2023-2025 | Evenity, Tavneos, Otezla |
| Janssen Biotech, INC. | $2,051.65 | 2022-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $1,374.55 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $956.50 | 2022-2025 | Lupkynis |
| Ucb, INC. | $714.04 | 2023-2025 | Bimzelx, Cimzia |
| Ani Pharmaceuticals, INC. | $635.50 | 2023-2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $554.61 | 2023-2025 | |
| Lilly USA, LLC | $516.70 | 2023-2024 | Taltz |
| Astrazeneca Pharmaceuticals LP | $410.22 | 2023-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $353.69 | 2023-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $351.82 | 2024-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $339.88 | 2022-2025 | Strensiq, Ultomiris |
| Pfizer INC. | $269.78 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.31 | 2023-2024 | Cyltezo |
| Tersera Therapeutics LLC | $183.41 | 2023-2024 | Quzyttir |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $166.11 | 2023-2024 | Idacio |
| Radius Health, INC. | $143.22 | 2023-2025 | Tymlos |
| Scilex Pharmaceuticals INC. | $76.14 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $71.19 | 2024 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $47.32 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $47.18 | 2025 | Orencia |
| Alvogen INC | $47.15 | 2024-2025 | Teriparatide |
| Sandoz INC. | $43.19 | 2024-2025 | Hyrimoz |
| Kyowa Kirin, INC. | $20.83 | 2024 | Crysvita |
| Tonix Medicines, INC. | $18.76 | 2025 | Tonmya |
| Kiniksa Pharmaceuticals, LTD. | $17.53 | 2023 | Arcalyst |
| Genentech USA, INC. | $13.46 | 2024 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yanique Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.